Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 20/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6875340 | 0.96 | GHSR (0.82) | GHSR | |
| SCHEMBL6875331 | 0.90 | GHSR (0.78) | GHSR | |
| SCHEMBL6874832 | 0.89 | GHSR (0.63) | GHSR | |
| SCHEMBL6875076 | 0.89 | GHSR (0.61) | GHSR | |
| SCHEMBL6877112 | 0.88 | GHSR (0.75) | GHSR | |
| SCHEMBL13552233 | 0.88 | GHSR (0.75) | GHSR | |
| SCHEMBL6879137 | 0.87 | GHSR (0.65) | GHSR | |
| SCHEMBL13552239 | 0.86 | GHSR (0.80) | GHSR | |
| SCHEMBL6877216 | 0.86 | GHSR (0.80) | GHSR | |
| SCHEMBL13552230 | 0.86 | GHSR (0.85) | GHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120270769-A1 | METHODS OF USING MACROCYCLIC INHIBITORS OF SERINE PROTEASE ENZYMES | TRANZYME PHARMA INC. (CA) | 2012-10-25 | — | — | US | disclosed |
| US-20120270769-A1 | METHODS OF USING MACROCYCLIC INHIBITORS OF SERINE PROTEASE ENZYMES | TRANZYME PHARMA INC. (CA) | 2012-10-25 | — | — | US | disclosed |
| US-20120270807-A1 | MACROCYCLIC INHIBITORS OF SERINE PROTEASE ENZYMES | TRANZYME PHARMA INC. (CA) | 2012-10-25 | — | — | US | disclosed |
| US-20120270807-A1 | MACROCYCLIC INHIBITORS OF SERINE PROTEASE ENZYMES | TRANZYME PHARMA INC. (CA) | 2012-10-25 | — | — | US | disclosed |
| WO-2011050270-A2 | MACROCYCLIC INHIBITORS OF SERINE PROTEASE ENZYMES | TRANZYME PHARMA, INC. (US) | 2011-04-28 | — | — | WO | disclosed |
| WO-2011050276-A1 | METHODS OF USING MACROCYCLIC INHIBITORS OF SERINE PROTEASE ENZYMES | TRANZYME PHARMA, INC. (US) | 2011-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270769-A1 | METHODS OF USING MACROCYCLIC INHIBITORS OF SERINE PROTEASE ENZYMES | PRSS1, SPINT2, TMPRSS15 | GHSR 4321/4885 |
| US-20120270807-A1 | MACROCYCLIC INHIBITORS OF SERINE PROTEASE ENZYMES | PRSS1, SPINT2, SERPINB1 | GHSR 4071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.